News Polaris Group

Equities

6550

KYG7171A1085

End-of-day quote Taiwan S.E. Other stock markets 03:30:00 27/06/2024 am IST			5-day change	1st Jan Change
72.7 ^TWD	-0.82%		+0.97%	-3.84%

25/06	Polaris Group Announces CFO Changes	CI
15/05	Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Polaris Group Announces CFO Changes	25/06	CI
Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA	15/05	CI
Polaris Group Announces Change of the Member of Compensation Committee	14/05	CI
Polaris Group Announces Change of the Member of Audit Committee	03/05	CI
Polaris Group acquired an additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.	23/12	CI
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth	22/12	GL
Polaris Group Announces the Appointment of K Evin Wu	21/12	CI
Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023	21/12	CI
Polaris Group agreed to acquire additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.	21/12	CI
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	04/12	GL
Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	04/12	AQ
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study	30/11	GL
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20 in Phase II Clinical Trial for NASH at Chang Gung Memorial Hospital, Linkou, Taiwan	29/11	CI
Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	17/11	GL
Polaris Group Initiates Rolling Submission of Biologic License Application for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	17/11	CI
Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11/11	CI
Polaris Group announced a financing transaction	06/23/06	CI
Polaris Group Appoints K.C. Tsai as Compensation Committee Member	26/23/26	CI
TDW HK Limited announced that it has received $17 million in funding from Polaris Group	26/23/26	CI
Polaris Group Announces Resignation of TAI, JANG-HUEI as Audit Committee and Remuneration Committee Member	29/23/29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Polaris Group

Equities

6550

KYG7171A1085

Summary

Filters